Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Brief Title

Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Official Title

A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia

Brief Summary

      This pilot clinical trial studies sirolimus, idarubicin, and cytarabine in treating patients
      with newly diagnosed acute myeloid leukemia. Sirolimus may stop the growth of cancer cells by
      blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as
      idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either
      by killing the cells or by stopping them from dividing. Giving sirolimus together with
      idarubicin and cytarabine may kill more cancer cells.
    

Detailed Description

      PRIMARY OBJECTIVES:

      1) To determine whether there is an association between baseline mammalian target of
      rapamycin (mTOR) activation paired with mTOR target inhibition post-treatment in leukemic
      blasts and clinical response in patients with newly diagnosed acute myeloid leukemia (AML)
      treated with sirolimus idarubicin/cytarabine.

      SECONDARY OBJECTIVES:

        1. To estimate the response rate of sirolimus idarubicin/cytarabine in patients with newly
           diagnosed AML compared to historical data using idarubicin/cytarabine alone.

        2. To determine the ability of oral sirolimus to inhibit mTOR in leukemic blasts.

        3. To assess if mTOR pathway inhibition correlates with clinical response.

        4. To collect further information on the safety, tolerability, and efficacy of sirolimus in
           combination with idarubicin/cytarabine in patients with newly diagnosed AML.

        5. To describe the progression-free survival and overall survival (1 year, 2 year and 5
           year) of patients treated with sirolimus idarubicin/cytarabine.

      OUTLINE:

      Patients receive sirolimus orally (PO) once daily (QD) on days 1-10, idarubicin intravenously
      (IV) over 3-5 minutes on days 4-6, and cytarabine IV continuously over 24 hours on days 4-10.

      After completion of study treatment, patients are followed up every 3 months for 5 years.
    

Study Phase

Early Phase 1

Study Type

Interventional

Primary Outcome

Change in measurement of mTOR activation paired with mTOR target inhibition

Secondary Outcome

 Overall survival

Condition

Adult Acute Megakaryoblastic Leukemia (M7)

Intervention

Sirolimus

Study Arms / Comparison Groups

 Treatment (sirolimus, idarubicin, cytarabine)

Description:  Patients receive sirolimus PO QD on days 1-10, idarubicin IV over 3-5 minutes on days 4-6, and cytarabine IV continuously over 24 hours on days 4-10.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Status

Drug

Estimated Enrollment

55

Start Date

March 15, 2013

Completion Date

December 12, 2019

Primary Completion Date

December 12, 2019

Eligibility Criteria

        Inclusion Criteria:

          1. Patients must have histologic evidence of newly diagnosed acute myeloid leukemia
             (non-M3 AML) as documented by the presence of >20% myeloid blasts in the bone marrow

          2. Subjects must be 18 years of age and <= 60

          3. Subjects must have an ECOG performance status of 2 or less. (see attachment 1).

          4. Subjects must have a life expectancy of at least 4 weeks.

          5. Subjects must be able to consume oral medication.

          6. Required initial laboratory values: Creatinine 2.0mg/dL; total or direct bilirubin
             1.5mg/dL; SGPT(ALT) 3xULN (if not due to the leukemia itself); negative pregnancy test
             for women with child-bearing potential.

          7. Patients must be able to sign consent and be willing and able to comply with scheduled
             visits, treatment plan and laboratory testing.

          8. Subjects must have a left ventricular ejection fraction (LVEF) of >/= 45%.

        Exclusion Criteria:

          1. Subjects with APL - FAB M3 (t(15;17)(q22;q21)[PML-RAR] are not eligible

          2. Subjects must not have received any chemotherapeutic agents for the AML (except
             Hydroxyurea). Intrathecal ARA-C and intrathecal methotrexate are permissible (as they
             are not systemic and only isolated to the central nervous system).

          3. Subjects must not be receiving growth factors, except for erythropoietin.

          4. Subjects with a "currently active" second malignancy, other than non-melanoma skin
             cancers are not eligible.

          5. Subjects with uncontrolled high blood pressure, unstable angina, symptomatic
             congestive heart failure, myocardial infarction within the past 6 months or serious
             uncontrolled cardiac arrhythmia are not eligible.

          6. Subjects taking the following are not eligible:

               1. Carbamazepine (e.g., Tegretol)

               2. Rifabutin (e.g., Mycobutin)

               3. Rifampin (e.g., Rifadin)

               4. Rifapentine (e.g., Priftin)

               5. St. John's wort

               6. Clarithromycin (e.g., Biaxin)

               7. Cyclosporine (e.g. Neoral or Sandimmune)

               8. Diltiazem (e.g., Cardizem)

               9. Erythromycin (e.g., Akne-Mycin, Ery-Tab)

              10. Itraconazole (e.g., Sporanox)

              11. Ketoconazole (e.g., Nizoral)

              12. Telithromycin (e.g., Ketek)

              13. Verapamil (e.g., Calan SR, Isoptin, Verelan)

              14. Voriconazole (e.g., VFEND)

              15. Tacrolimus (e.g. Prograf)

          7. Subjects taking fluconazole, voriconazole, itraconazole, posaconazole, and
             ketoconazole within 72 hours of study entry are not eligible. Reinstitution of
             fluconazole, voriconazole, itraconazole, posaconazole, ketoconazole and diltiazem is
             permissible 72 hours after the last dose of sirolimus.

          8. Subjects who require HIV protease inhibitors or those with AIDS-related illness

          9. Subjects with other severe concurrent disease which in the judgment of the
             investigator would make the patient inappropriate for entry into this study are
             ineligible.

         10. Subjects must not be pregnant or breastfeeding. Pregnancy tests must be obtained for
             all females of child-bearing potential. Pregnant or lactating patients are ineligible
             for this study due to the unknown human fetal or teratogenic toxicities of sirolimus.
             Males or females of reproductive age may not participate unless they have agreed to
             use an effective contraceptive method.

         11. Subjects who have uncontrolled infection are not eligible. Patients must have any
             active infections under control. Fungal disease must be stable for at least 2 weeks
             before study entry.

         12. Subjects with bacteremia must have documented negative blood cultures prior to study
             entry.
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Margaret Kasner, MD, , 

Location Countries

United States

Location Countries

United States

NCT ID

NCT01822015

Organization ID

12D.588

Secondary IDs

2012-55

Responsible Party

Sponsor

Study Sponsor

Sidney Kimmel Cancer Center at Thomas Jefferson University

Study Sponsor

Margaret Kasner, MD, Principal Investigator, Thomas Jefferson University

Verification Date

February 2023